Core Viewpoint - Haicheng Pharmaceutical has successfully renewed the inclusion of its injectable Labetalol Hydrochloride (50mg) and has achieved the first-time inclusion of injectable Labetalol Hydrochloride (150mg) in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1] Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released a notification regarding the updated drug catalog for 2025 [1] - The successful renewal of the 50mg formulation indicates continued support for Haicheng Pharmaceutical's product line [1] - The first-time inclusion of the 150mg formulation expands the company's market access and potential revenue streams [1]

证券代码：300584 证券简称：海辰药业 公告编号：2025-054 南京海辰药业股份有限公司 药品分类：选择性β-受体阻滞剂 是否独家品种：是 关于公司注射用盐酸兰地洛尔被纳入国家医保目录的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 12 月 7 日，国家医保局、人力资源社会保障部发布了《关于印发< 国家基本医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创新药 品目录>（2025 年）的通知》（医保发〔2025〕33 号），南京海辰药业股份有 限公司（以下简称"公司"）注射用盐酸兰地洛尔（50mg）续约成功,注射用盐 酸兰地洛尔（150mg）首次纳入《国家基本医疗保险、工伤保险和生育保险药品 目录（2025 年）》（以下简称"国家医保目录"）。具体情况如下： （一）药品名称：注射用盐酸兰地洛尔（50mg） 一、纳入国家医保目录的情况说明 医保支付标准：维持原支付标准，168 元（50mg/支） 限定支付范围：维持原限定支付范围，即限：1、手术过程中发生的下列快 速性心律失常的紧急治疗：心房纤颤、心房扑动、窦性心动过速；2、 ...

Group 1 - The company Hai Chen Pharmaceutical (300584.SZ) is currently preparing for the production launch of its VC project [1] - The lithium sulfide project is undergoing pilot production testing [1]

Core Viewpoint - Haicheng Pharmaceutical (300584) is currently preparing for the production launch of its VC project and is conducting pilot production for its lithium sulfide project [1] Group 1 - The company is in the pre-production preparation phase for its VC project [1] - The lithium sulfide project is undergoing pilot production testing [1]

Core Viewpoint - Haicheng Pharmaceutical (300584.SZ) is currently preparing for the production launch of its VC project and is conducting pilot production for its lithium sulfide project [1] Group 1 - The company is in the pre-production preparation phase for its VC project [1] - The lithium sulfide project is undergoing pilot production testing [1]

Group 1 - The core viewpoint of the news is that Hainan Pharmaceutical's stock has experienced significant fluctuations, with a year-to-date increase of 189.48% but a recent decline of 19.24% over the last five trading days [1] - As of November 21, Hainan Pharmaceutical's stock price was 58.07 yuan per share, with a market capitalization of 6.968 billion yuan [1] - The company has seen a net outflow of 929,000 yuan in principal funds, with large orders showing a buy of 9.1799 million yuan and a sell of 11.4989 million yuan [1] Group 2 - Hainan Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, focuses on the research, production, and sales of chemical preparations, raw materials, and intermediates [2] - The main business revenue composition includes cardiovascular drugs (87.12%), antibiotics (5.69%), and other categories [2] - As of November 10, the number of shareholders was 22,100, a decrease of 2.84%, with an average of 3,709 circulating shares per person, an increase of 2.93% [2] Group 3 - Hainan Pharmaceutical has distributed a total of 161 million yuan in dividends since its A-share listing, with 18 million yuan in the last three years [3] - As of September 30, 2025, new institutional shareholders include several funds, with notable holdings from China Europe Enjoy Life Mixed A and Huazhang Medical Biological Stock Initiation A [3]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.23% on November 20, with Minsheng Health leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hainan Haiyao (000566) with a closing price of 7.92, up 10.00% and a trading volume of 2.1875 million shares, totaling 1.634 billion yuan [1] - Kangyi Pharmaceutical (300086) closed at 12.15, up 8.97% with a trading volume of 1.4039 million shares, totaling 1.656 billion yuan [1] - Other significant gainers included Bibete (688759), Yuekang Pharmaceutical (688658), and Qianyan Bio (688221) with increases ranging from 5.43% to 7.73% [1] - Conversely, the following stocks faced declines: - Minsheng Health (301507) closed at 16.69, down 6.18% with a trading volume of 273,400 shares, totaling 463 million yuan [2] - Shanhua Pharmaceutical (300452) and Hasa Lian (002900) also saw declines of 4.45% and 4.12% respectively [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.233 billion yuan from institutional investors, while retail investors contributed a net inflow of 964 million yuan [2] - Notable capital flows included: - Hainan Haiyao (000566) had a net inflow of 25.3 million yuan from institutional investors, but a net outflow of 101 million yuan from retail investors [3] - Kangyi Pharmaceutical (300086) experienced a net inflow of 56.4 million yuan from institutional investors, while retail investors saw a net outflow of 67.9 million yuan [3]

Core Viewpoint - On November 18, Haisun Pharmaceutical experienced a decline of 5.19%, with a stock price of 65.55 CNY per share, a trading volume of 397 million CNY, a turnover rate of 7.14%, and a total market capitalization of 7.866 billion CNY [1] Company Overview - Nanjing Haisun Pharmaceutical Co., Ltd. is located at No. 1 Hengfa Road, Nanjing Economic and Technological Development Zone, Jiangsu Province, and was established on January 15, 2003, with its listing date on January 12, 2017 [1] - The company's main business involves the research, development, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] Revenue Composition - The revenue composition of Haisun Pharmaceutical is as follows: - Cardiovascular drugs: 87.12% - Antibiotics: 5.69% - Active pharmaceutical ingredients and intermediates: 1.68% - Digestive drugs: 1.50% - Antiviral drugs: 1.47% - Others (supplements): 0.83% - Immune regulators: 0.80% - Other categories: 0.57% - Diuretics: 0.34% [1] Shareholder Information - Among the top ten circulating shareholders of Haisun Pharmaceutical, a fund under China Europe Fund ranks as a new entrant in the third quarter, holding 937,000 shares, which accounts for 1.14% of the circulating shares [2] - The estimated floating loss for this fund today is approximately 3.3638 million CNY [2] Fund Performance - The China Europe Enjoy Life Mixed A Fund (010336) was established on January 7, 2021, with a latest scale of 2.004 billion CNY [2] - Year-to-date return is 13.68%, ranking 5257 out of 8140 in its category; the one-year return is 12.32%, ranking 5349 out of 8057; since inception, the fund has incurred a loss of 47.66% [2] Fund Manager Information - The fund manager of China Europe Enjoy Life Mixed A is Qian Yafeng, who has a cumulative tenure of 10 years and 118 days [3] - The total asset scale of the fund is 2.496 billion CNY, with the best fund return during the tenure being 242.9% and the worst being -24.02% [3]

Core Viewpoint - Haisun Pharmaceutical's stock has experienced significant growth this year, with a year-to-date increase of 237.69%, and recent trading activity shows continued interest from institutional investors [2][3]. Group 1: Stock Performance - As of November 18, Haisun Pharmaceutical's stock price was 67.74 CNY per share, with a market capitalization of 8.129 billion CNY [1]. - The stock has seen a rise of 18.68% over the past five trading days, 19.34% over the past 20 days, and 14.81% over the past 60 days [2]. - The company has appeared on the "Dragon and Tiger List" eight times this year, with the most recent net buy of 62.603 million CNY on November 14 [2]. Group 2: Financial Performance - For the period from January to September 2025, Haisun Pharmaceutical reported revenue of 472 million CNY, reflecting a year-on-year growth of 30.80%, and a net profit attributable to shareholders of 32.6785 million CNY, up 16.22% year-on-year [3]. - Cumulative cash dividends since the company's A-share listing amount to 161 million CNY, with 18 million CNY distributed over the past three years [4]. Group 3: Shareholder Structure - As of November 10, the number of shareholders for Haisun Pharmaceutical was 22,100, a decrease of 2.84% from the previous period, with an average of 3,709 circulating shares per shareholder, an increase of 2.93% [3]. - New institutional shareholders include several funds, such as China Europe Enjoy Life Mixed A and Huashan Pharmaceutical Biological Stock Initiation A, indicating growing institutional interest [4]. Group 4: Business Overview - Haisun Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, specializes in the research, production, and sales of chemical preparations, raw materials, and intermediates [2]. - The company's main revenue sources include cardiovascular drugs (87.12%), antibiotics (5.69%), and other therapeutic categories [2].

Core Viewpoint - The company, Hecen Pharmaceutical, has provided insights into its production capacity for electrolyte additives and its involvement in solid-state battery materials, specifically lithium sulfide and binders, as detailed in its periodic reports [1] Group 1: Production Capacity - The company has disclosed that its detailed production capacity for electrolyte additives can be found in its historical periodic reports [1] - Currently, the company primarily supplies domestic electrolyte manufacturers [1] Group 2: Solid-State Battery Involvement - The company is actively engaged in the solid-state battery sector, focusing on lithium sulfide and binder materials [1] - Further details regarding the company's activities in this area are available in its periodic reports [1]